Synthetic lethal therapies for cancer: what's next after PARP inhibitors?

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Synthetic lethality is a genetic interaction where mutations in two or more genes lead to cell death.
• Poly(ADP-ribose) polymerase (PARP) inhibitors have shown clinical efficacy in cancers with BRCA1/BRCA2 mutations, validating the synthetic lethality concept.
• PARP inhibitors are approved for BRCA-mutant ovarian and breast cancers and show promise in prostate cancer.

Purpose of the Study:

• To review other discovered synthetic lethal interactions in cancer.
• To discuss principles for increasing clinical efficacy of synthetic lethality-based therapies.
• To highlight new computational and experimental approaches for discovering and validating synthetic lethal interactions.

Main Methods:

• Review of existing literature on synthetic lethality in cancer.
• Discussion of underlying principles and emerging discovery platforms.
• Exploration of future research directions and challenges.

Main Results:

• Clinical validation of synthetic lethality through PARP inhibitors in BRCA-mutant cancers.
• Demonstrated efficacy of PARP inhibitors in ovarian, breast, and prostate cancers.
• Identification of numerous other synthetic lethal interactions with potential clinical applications.

Conclusions:

• The synthetic lethality concept is clinically validated and offers a promising therapeutic strategy for cancer treatment.
• Advancements in computational and experimental methods are accelerating the discovery of novel synthetic lethal interactions.
• Future research should focus on expanding the application of synthetic lethality to a broader range of cancers and patient populations.